Enanta Pharmaceuticals to Present at Upcoming Investor Conferences
March 02 2021 - 6:01AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, will present
at three upcoming virtual investor conferences:
- H.C. Wainwright & Co. Global Life Sciences Conference:
Corporate presentation available for on-demand viewing on Tuesday,
March 9, 2021
- 33rd Annual Roth Conference: Panel presentation “Therapies and
Vaccines in the Fight Against COVID-19” on Monday, March 15, 2021
at 3:00 p.m. ET and corporate presentation available for on-demand
viewing on Tuesday, March 9, 2021
- Oppenheimer & Co. 31st Annual Healthcare Conference:
Corporate presentation on Tuesday, March 16, 2021 at 8:00 a.m.
ET
Webcasts of each event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of each webcast will
be available following the presentations and will be archived for
approximately 90 days.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV)
and non-alcoholic steatohepatitis (NASH). Enanta is also conducting
research in human metapneumovirus (hMPV) and SARS-CoV-2
(COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302005290/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024